BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced that it has strengthened its management team with the appointment of Judith Greciet as Deputy Chief Operating Officer, in charge of Operations and R&D.
Judith Greciet joins from Eisai France, a company she managed as President for 3 years. Eisai France, with a €120 million turnover, is focused on high value products in the Alzheimer’s disease, a field in which it is one of the world leaders.
Judith Greciet has an exemplary career in the pharmaceutical industry and international groups. Aged 41, she holds a doctorate of pharmacy in addition to being a graduate of 3rd cycle management and pharmaceutical marketing.
Judith Greciet joined Eisai France in June 2007 after successful achievements at Wyeth Pharmaceuticals France (today Pfizer), LFB Group (“Laboratoire Français du fractionnement et des Biotechnologies”, a French bio-pharmaceutical company), Zeneca and Pharmacia, where she hold increasing operational and strategic positions involving a managerial scope. She particularly focused on optimizing links with all health actors (researchers, academic practitioners, medical doctors, patient associations, health authorities…). She exercised her talents in the oncology and immunology areas with innovative products such as Enbrel (in rheumatology). She has served successively as Head of the Oncology Department and of the Hospital Department where she was notably in charge of hospital antibiotherapy projects.
Dominique Costantini, co-founder and Chief Executive Officer of BioAlliance Pharma explains: “As Deputy Chief Operating Officer, Judith Greciet represents the entry of a new generation in the drug industry. She will focus on BioAlliance’s operations and coordinate the development activities of the Company. Thanks to her expertise, she will also contribute to implement new partnerships and to define the Company’s strategic orientations. Judith will as well collaborate to the relationships with the financial community. We are delighted to welcome her and are looking forward to this next phase of the development of BioAlliance Pharma”.